Antennova
Private Company
Funding information not available
Overview
Antennova is a private, pre-revenue biotech advancing a clinical-stage pipeline of four novel oncology assets targeting key immune pathways. Its portfolio includes an ADC, a small molecule inhibitor, and bispecific/monoclonal antibodies, all designed with differentiation to overcome limitations of existing therapies, such as targeting low antigen expressors or reversing checkpoint inhibitor resistance. The company leverages deep immuno-oncology expertise to create a synergistic portfolio aimed at combination therapies for a broad range of solid tumors and hematologic malignancies.
Technology Platform
Portfolio-based strategy focused on developing novel immuno-oncology and targeted therapy modalities (ADCs, bispecific antibodies, small molecules, monoclonal antibodies) with complementary mechanisms of action for proprietary combination therapies.
Opportunities
Risk Factors
Competitive Landscape
Antennova operates in the highly competitive immuno-oncology field, facing rivals for each target, from large pharma to other biotechs. Its success hinges on proving its claimed differentiators—like targeting Claudin 18.2 low expressors or a safer 4-1BB agonist—in clinical trials to secure a distinct position. The portfolio's combination potential is a strategic advantage but also requires demonstrating superior efficacy to established standards of care.